Ki67 as a prognostic factor of craniopharyngioma's recurrence in paediatric population

Childs Nerv Syst. 2020 Jul;36(7):1461-1469. doi: 10.1007/s00381-020-04519-4. Epub 2020 Feb 7.

Abstract

Purpose: Craniopharyngioma is one of the most frequent benign tumours of the central nervous system in the paediatric population. Although it is a benign tumour according to the WHO classification, it significantly deteriorates the patient's quality of life. The aim of this study is to assess if proliferation index Ki67 can be a useful marker of the risk of craniopharyngioma's recurrence.

Methods: Expression of Ki67 was examined in 85 specimens of primary craniopharyngioma and in 11 specimens of the recurring tumour. In all the cases, adamantinomatous type of craniopharyngioma was diagnosed. Values of Ki67 expression were compared between patients with and without recurrence, between patients with progression and relapse and between primary and recurrent tumours.

Results: No statistically significant differences were found between proliferation index Ki67 values in tumours with recurrence and without (median values 2.5% and 3%, respectively, p = 0.69). The median value of proliferation index Ki67 in progression group was 1% and in the relapse group 4%; no statistical significance between those groups was found (p = 0.067). The median value of proliferation index Ki67 in primary tumours was 3% (0-20%) and in recurrent tumours it was 5% (0-14%). Despite the lack of statistical significance (p = 0.61), a tendency towards higher values of Ki67 in recurring tumours in comparison with primary tumours was shown.

Conclusions: Proliferation index Ki67 is not a reliable prognostic factor of craniopharyngioma's recurrence.

Keywords: Children; Hypopituitarism; Progression; Relapse; Sellar.

MeSH terms

  • Child
  • Craniopharyngioma*
  • Humans
  • Ki-67 Antigen
  • Neoplasm Recurrence, Local
  • Pituitary Neoplasms*
  • Prognosis
  • Quality of Life

Substances

  • Ki-67 Antigen